Rebus Holdings, Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
Rebus Holdings, Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Rebus Holdings, Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Rebus Holdings, Inc. Competitors
Rebus Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans